Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou(Tongji University), Changxuan You(Southern Medical University), C. Wang(Tianjin Medical University Cancer Institute and Hospital), Shengxiang Ren(Tongji University), Lin Chen(Shantou University), J. Wang(Peking University), Y. Zhang(Zhejiang Cancer Hospital), G. Chen(Harbin Medical University), Yi Luo(Kunming Institute of Botany), M. Ye(Shanghai Jiao Tong University), Chengping Hu(Central South University), L. Zhang(Sun Yat-sen University), W. F. Mader(Harbin Institute of Petroleum), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Songwen Zhou(Tongji University), Juanjuan Huang(Ningbo University), S. Zhang(Capital Medical University), J. Feng(Hangzhou First People's Hospital), Xuetong Liu(Academy of Military Medical Sciences), Shun Lü(Shanghai Jiao Tong University), Qingyu Xiu(Second Military Medical University), L. Zhang(University of Manchester)
Annals of Oncology
July 4, 2015
10.1093/annonc/mdv276
Cited by 467

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k